TORONTO, Nov. 25, 2019 /CNW/ - PharmaCielo
Ltd. ("PharmaCielo" or the
"Company") (TSXV:PCLO, OTCQX: PCLOF), the
Canadian parent of Colombia's
premier cultivator and producer of medicinal-grade cannabis
extracts, PharmaCielo Colombia Holdings S.A.S., announces today
that it will host a conference call on Monday, November 25th, 2019, at
5:00 p.m. ET to discuss its third
quarter financial results and provide investors with key business
highlights. The call will be chaired by David Attard, CEO; David
Gordon, CCO and Scott
Laitinen, CFO.
CONFERENCE CALL DETAILS
Date: November
25th, 2019 | Time: 5:00pm
ET
Participant Dial-in: 416-764-8688 or
1-888-390-0546
Replay Dial-in: 416-764-8677 or
1-888-390-0541
(Available for 2 weeks)
Conference ID: 30043730
Playback #: 043730
Listen to webcast: event.on24.com
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO, OTCQX:PCLOF) is a global company,
headquartered in Canada, with a
focus on ethical and sustainable processing and supplying of all
natural, medicinal-grade cannabis oil extracts and related products
to large channel distributors. PharmaCielo's principal (and wholly
owned) subsidiary is PharmaCielo Colombia Holdings S.A.S.,
headquartered at its nursery and propagation centre located in
Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
For further information:
www.PharmaCielo.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE PharmaCielo Ltd.